Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 8/20 | 0.40 |
| ▸ | MMP9 | P14780 | 7/20 | 0.40 |
| ▸ | MMP8 | P22894 | 5/20 | 0.40 |
| ▸ | MMP1 | P03956 | 14/20 | 0.39 |
| ▸ | MMP3 | P08254 | 8/20 | 0.39 |
| ▸ | PYGL | P06737 | 1/20 | 0.38 |
| ▸ | FCER2 | P06734 | 2/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.36 |
| ▸ | KLK1 | P06870 | 1/20 | 0.36 |
| ▸ | MMP7 | P09237 | 2/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8712433 | 0.83 | KLKB1 (0.41) | MMP2MMP9MMP1MMP3KLKB1 | |
| SCHEMBL6324008 | 0.76 | CTSL (0.39) | MMP2MMP9MMP8PYGLKLKB1 | |
| SCHEMBL7190417 | 0.75 | MMP9 (0.31) | MMP2MMP9MMP8MMP1MMP3 | |
| SCHEMBL6403197 | 0.74 | MMP9 (0.42) | MMP9MMP8MMP3PYGL | |
| SCHEMBL8227714 | 0.73 | CYP2D6 (0.39) | MMP2MMP9MMP8MMP1FCER2 | |
| SCHEMBL7190412 | 0.71 | CTSL (0.36) | MMP2MMP9MMP8MMP1MMP3 | |
| SCHEMBL6323718 | 0.71 | GHSR (0.41) | MMP3KLKB1KLK1CTSSCTSK | |
| SCHEMBL6326249 | 0.71 | CTSL (0.41) | MMP2MMP9MMP8PYGLKLKB1 | |
| SCHEMBL6318207 | 0.70 | KLKB1 (0.39) | MMP2MMP9MMP8MMP1MMP3 | |
| SCHEMBL6320214 | 0.69 | HRH4 (0.37) | MMP2MMP9MMP8KLKB1KLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6939880-B2 | Compounds with growth hormone releasing properties | NOVO NORDISK A/S (DK) | 2005-09-06 | — | — | US | disclosed |
| US-20030055261-A1 | Compounds with growth hormone releasing properties | HELSINN THERAPEUTICS (U.S.), INC. | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055261-A1 | Compounds with growth hormone releasing properties | GHRHR, GHSR, IGFBP1 | MMP2 2439/4885MMP9 2831/4885MMP8 4280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.